Osborne Clarke has advised the syndicate of institutional investors, who included Imperial Innovations and Invesco Perpetual on the £581m flotation of Circassia on the London Main Market.

Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies.

Circassia is the first biotech company to list on the London's Main Market since 2006 and it is believed to be the biggest biotech company to ever IPO on the London Markets.

The Osborne Clarke team consisted Partners Rob Wood, Ray Coyle, Jonathan King and James Massy-Collier.

Osborne Clarke previously advised the syndicate on all of the previous funding rounds. The latest, in 2012 raised £72m.